EGFR and non-small cell lung carcinoma: We next used osimertinib to suppress EGFR–AKT signaling in EGFR-mutant NSCLC cells and found that the incubation of osimertinib led to decreased expression of AADAT in NCI-H1975, HCC827, and HCC4006 (Figure 6C).